The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: A case report

Alternative Medicine Review

Volumn 7, Issue 5, 2002, Pages 410-417

  Logan, Alan C ^a   Beaulne, Tracey M ^a  

^a Unit 4   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; METHANE; PEPPERMINT OIL;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; CASE REPORT; CLINICAL EXAMINATION; DRUG EFFICACY; ENTERIC COATED TABLET; FEMALE; HUMAN; HYDROGEN BREATH TEST; INTESTINE FLORA; IRRITABLE COLON;

ADULT; ANTI-BACTERIAL AGENTS; COLONIC DISEASES, FUNCTIONAL; FEMALE; HUMANS; INTESTINE, SMALL; PLANT OILS; TABLETS, ENTERIC-COATED;

EID: 0036801137     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Mitsuoka T. Recent trends in research on intestinal flora. Bifido Microflora 1982;1:3-24.
2. Toskes PP. Bacterial overgrowth of the gastrointestinal tract. Adv Intern Med 1993;38:387-407.
3. Metz G, Gassull MA, Drasar BS, et al. Breath-hydrogen test for small-intestinal bacterial colonisation. Lancet 1976;1:668-669.
4. Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol 1979;14:333-336.
5. King CE, Toskes PP. Breath tests in the diagnosis of small intestine bacterial overgrowth. Crit Rev Clin Lab Sci 1984;21:269-281.
6. Wang J, Bei L, Pan G. Lactulose hydrogen breath test in small intestinal bacterial overgrowth. Zhonghua Nei Ke Za Zhi 1995;34:381-384. [Article in Chinese]
7. Holt PR. Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 1990;19:345-359.
8. Saltzman JR, Russell RM. The aging gut. Nutritional issues. Gastroenterol Clin North Am 1998;27:309-324.
9. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998;13:245-253.
10. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-3506.
11. Komaroff AL, Fagioli LR, Geiger AM, et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996;100:56-64.
12. Waylonis GW, Heck W. Fibromyalgia syndrome. New associations. Am J Phys Med Rehabil 1992;71:343-348.
13. Donaldson RM Jr. Role of enteric microorganisms in malabsorption. Fed Proc 1967;26:1426-1431.
14. King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology 1979;76:1035-1055.
15. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86:174-193.
16. Tabaqchali S. The pathophysiological role of small intestinal bacterial flora. Scand J Gastroenterol Suppl 1970;6:139-163.
17. Pimentel M, Chow EJ, Hallegua D, et al. Small intestinal bacterial overgrowth: a possible association with fibromyalgia. J Musculoskelet Pain 2001;9:107-113.
18. Pimentel M, Hallegua D, Chow EJ, et al. Eradication of small intestinal bacterial overgrowth decreases symptoms in chronic fatigue syndrome: a double blind, randomized study. Gastroenterology 2000;118:A414.
19. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000;5:93-108.
20. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999;354:936-939.
21. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000;160:221-227.
22. Gomborone JE, Gorard DA, Dewsnap PA, et al. Prevalence of irritable bowel syndrome in chronic fatigue. J R Coll Physicians Lond 1996;30:512-513.
23. Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: Different expressions of a common pathogenetic process. Br J Rheumatol 1991;30:220-222.
24. Caballero-Plasencia AM, Valenzuela-Barranco M, Herrerias-Gutierrez JM, Esteban-Carretero JM. Altered gastric emptying in patients with irritable bowel syndrome. Eur J Nucl Med 1999;26:404-409.
25. Bumet RB, Chatterton B. Gastrointestinal symptoms and gastric emptying studies in chronic fatigue syndrome. AHMF Clinical and Scientific Meeting. Sydney, Australia. 2001.
26. Husebye E, Hellstrom PM, Sundler F, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G368-G380.
27. Moleyar V, Narasimham P. Antibacterial activity of essential oil components. Int J Food Microbiol 1992;16:337-342.
28. Delaquis PJ, Stanich K, Girard B, Mazza G. Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. Int J Food Microbiol 2002;74:101-109.
29. Dorman HJ, Deans SG. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J Appl Microbiol 2000;88:308-316.
30. Pattnaik S, Subramanyam VR, Kole C. Antibacterial and antifungal activity of ten essential oils in vitro. Microbios 1996;86:237-246.
31. Pattnaik S, Subramanyam VR, Bapaji M, Kole CR. Antibacterial and antifungal activity of aromatic constituents of essential oils. Microbios 1997;89:39-46.
32. Farag RS, Daw ZY, Hewedi FM, El-Baroty GSA. Antimicrobial activity of some Egyptian spice essential oils. J Food Prot 1989;52:665-667.
33. Shapiro S, Meier A, Guggenheim B. The antimicrobial activity of essential oils and essential oil components toward oral bacteria. Oral Microbiol Immunol 1994;9:202-208.
34. Imai H, Osawa K, Yasuda H, et al. Inhibition by the essential oils of peppermint and spearmint of the growth of pathogenic bacteria. Microbios 2001;106:31-39.
35. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979;2:835-836.
36. Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicentre trial. Br J Clin Pract 1984;38:394, 398.
37. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-768.
38. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001;138:125-128.
39. Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001;134:815-822.
40. May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung 1996;46:1149-1153.
41. Freise J, Kohler S. Peppermint oil-caraway oil fixed combination in non-ulcer dyspepsia - comparison of the effects of enteric combinations. Pharmazie 1999;54:210-215. [Article in German]
42. Madisch A, Heydenreich CJ, Wieland V, et al. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study. Arzneimittelforschung 1999;49:925-932.
43. May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000;14:1671-1677.
44. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45 (Suppl 2):II43-II47.
45. Perman JA, Modler S, Barr RG, Rosenthal P. Fasting breath hydrogen concentration: normal values and clinical application. Gastroenterology 1984;87:1358-1363.
46. Joseph F Jr, Rosenberg AJ. Breath hydrogen testing: Diseased versus normal patients. J Pediatr Gastroenterol Nutr 1988;7:787-788.
47. Taylor BA, Luscombe DK, Duthie HL. Inhibitory effect of peppermint oil on gastrointestinal smooth muscle. Gut 1983;24:A992.
48. Taylor BA, Luscombe DK, Duthie HL. Inhibitory effect of peppermint oil and menthol on human isolated colon. Gut 1984;25:A1168-A1169.
49. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991;101:55-65.
50. Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000;14:20-23.
51. Leicester RJ, Hunt RH. Peppermint oil to reduce colonic spasm during endoscopy. Lancet 1982;2:989.
52. Jarvis LJ, Hogg H, Houghton CD. Topical peppermint oil for the relief of colonic spasm at barium enema. Clin Radiol 1992;46:435.
53. Gerards C, Leodolter A, Glasbrenner B, Malfertheiner P. H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Dig Dis 2001;19:170-173.
54. Gasbarrini A, De Luca A, Fiore G, et al. Beneficial effects of Helicobacter pylori eradication on migraine. Hepatogastroenterology 1998;45:765-770.
55. Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2:94-103.
56. Kelly GS. Hydrochloric acid: physiological functions and clinical implications. Altern Med Rev 1997;2:116-127.
57. Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998;27:155-160.
58. Kanamori Y, Hashizume K, Sugiyama M, et al. Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: A novel synbiotics therapy for intestinal failure. Dig Dis Sci 2001;46:2010-2016.
59. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1538.
60. Brigidi P, Vitali B, Swennen E, et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735-741.
61. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13:1143-1147.
62. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986;49:64-72.
63. Mangin I, Bourget N, Bouhnik Y, et al. Identification of Bifidobacterium strains by rRNA gene restriction patterns. Appl Environ Microbiol 1994;60:1451-1458.
64. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998;10:59-62.
65. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002;97:104-108.
66. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992;304:87-90.
67. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-415.
68. Longstreth GF. Irritable bowel syndrome: a multibillion-dollar problem. Gastroenterology 1995;109:2029-2031.
69. Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia. Disability and health-care use. Med Care 1996;34:924-930.
70. Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res 1996;9:13-17.
71. Donker GA, Foets M, Spreeuwenberg P. Patients with irritable bowel syndrome: health status and use of health care services. Br J Gen Pract 1999;49:787-792.
72. Ruddell WS, Axon AT, Findlay JM, et al. Effect of cimetidine on the gastric bacterial flora. Lancet 1980;1:672-674.
73. Ruddell WS, Losowsky MS. Severe diarrehoea due to small intestinal colonisation during cimetidine treatment. Br Med J 1980;281:273.
74. Deane S, Youngs D, Poxon V, et al. Cimetidine and gastric microflora. Br J Surg 1980;67:371.
75. Di Stefano M, Graziamaria V, Malservisi S, Corazza GR. Small intestine bacterial overgrowth and metabolic bone disease. Dig Dis Sci 2001;46:1077-1082.